| Ticker Symbol: | EPIX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 4 Maguire Road Lexington MA 02421 781-761-7600 |
| CEO/President: | Michael J. Astrue |
| Industry: | Medical - Drugs / Standard Industry Code: 2834 |
| Description: | EPIX Pharmaceuticals, Inc., based in Cambridge, MA, discovers and develops innovative pharmaceuticals for imaging that are designed to transform the diagnosis, treatment and monitoring of disease. They use their proprietary Target Visualization Technology to create imaging pharmaceuticals targeted at the molecular level, enabling physicians to use Magnetic Resonance Imaging to obtain detailed information about specific disease processes. The Company\'s lead product, MS-325, is the first imaging pharmaceutical specifically designed for Magnetic Resonance Angiography. |
| Shares Outstanding: | 41,360 (000) | Market Value: | 18,640 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 51.51% | Number of Inst.Shareholders: | 4.93% |
| Last Quarter Sales: | 17.35 ($Mil.) | Last Quarter Net Income: | -2.34 ($Mil.) |
| Last Quarter EPS: | -0.06 | P/E Ratio: | 0 |
| Most Recent Earnings: | -0.33 on 02/20/08 | Earnings Per Share: | -1.11 |
| Most Recent Split: | 10-15 on 08/17/06 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| PFIZER INC | -18.60 | 19.00 | |
| JOHNSON AND JOH | +2.10 | 66.16 | |
| MERCK CO INC | -40.70 | 31.78 | |
| BRISTOL MYERS S | -26.10 | 20.43 | |
| SCHERING PLOUGH | -45.30 | 16.44 |
